BioCentury | Feb 2, 2004
Emerging Company Profile

CORPORATE PROFILE

...million Investors: Accel Partners; Affymetrix Inc.; Bay City Capital; Brookside Capital Partners; Millennium Pharmaceuticals Inc.; Morgan Stanley Dean Witter...
BioCentury | Mar 25, 2002
Finance

Who's left?

...Discplined Growth 302,725 1.3% Edgewood 283,193 1.2% Kern Capital 252,700 1.1% Vanguard Group 252,154 1.1% Morgan Stanley Dean Witter...
BioCentury | Jan 14, 2002
Emerging Company Profile

Shantha: Biotech by necessity

...vaccine , human insulin delivery mechanisms, oral vaccine delivery, and monoclonal antibodies. In September 2000, Morgan Stanley Dean Witter...
BioCentury | Jan 14, 2002
Emerging Company Profile

Corporate Profile

...Number of employees: 372 Funds raised: $10.2 million Investors: State Bank of India Mutual Fund; Morgan Stanley Dean Witter...
BioCentury | Aug 27, 2001
Finance

Ebb & Flow

...shares was sold at a low price on Wednesday and the stock continued to fall. Morgan Stanley Dean Witter...
BioCentury | Jun 11, 2001
Finance

Analyst picks & changes

...his 2001 and 2002 EPS estimates to $0.70 and $1.02 from $0.60 and $0.96, respectively. Morgan Stanley Dean Witter...
BioCentury | Apr 18, 2001
Financial News

Novazyme raises $16 million

...private financing. Investors included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Catalyst Health & Technology Partners; and Morgan Stanley Dean Witter...
BioCentury | Feb 2, 2001
Top Story

Aviron raises $400 million

...and the other $200 million from a convertible note deal. Both deals were underwritten by Morgan Stanley Dean Witter...
BioCentury | Jan 12, 2001
Top Story

Aviron to sell follow-on, notes

...proposed a $150 million offering of convertible subordinated notes. The deals will be underwritten by Morgan Stanley Dean Witter...
BioCentury | Dec 27, 2000
Financial News

Rigel sells shoe

...IPO. The sale brings to $39.6 million the total raised in the deal, underwritten by Morgan Stanley Dean Witter...
Items per page:
1 - 10 of 65
BioCentury | Feb 2, 2004
Emerging Company Profile

CORPORATE PROFILE

...million Investors: Accel Partners; Affymetrix Inc.; Bay City Capital; Brookside Capital Partners; Millennium Pharmaceuticals Inc.; Morgan Stanley Dean Witter...
BioCentury | Mar 25, 2002
Finance

Who's left?

...Discplined Growth 302,725 1.3% Edgewood 283,193 1.2% Kern Capital 252,700 1.1% Vanguard Group 252,154 1.1% Morgan Stanley Dean Witter...
BioCentury | Jan 14, 2002
Emerging Company Profile

Shantha: Biotech by necessity

...vaccine , human insulin delivery mechanisms, oral vaccine delivery, and monoclonal antibodies. In September 2000, Morgan Stanley Dean Witter...
BioCentury | Jan 14, 2002
Emerging Company Profile

Corporate Profile

...Number of employees: 372 Funds raised: $10.2 million Investors: State Bank of India Mutual Fund; Morgan Stanley Dean Witter...
BioCentury | Aug 27, 2001
Finance

Ebb & Flow

...shares was sold at a low price on Wednesday and the stock continued to fall. Morgan Stanley Dean Witter...
BioCentury | Jun 11, 2001
Finance

Analyst picks & changes

...his 2001 and 2002 EPS estimates to $0.70 and $1.02 from $0.60 and $0.96, respectively. Morgan Stanley Dean Witter...
BioCentury | Apr 18, 2001
Financial News

Novazyme raises $16 million

...private financing. Investors included Perseus-Soros Biopharmaceutical Fund; HealthCare Ventures; Catalyst Health & Technology Partners; and Morgan Stanley Dean Witter...
BioCentury | Feb 2, 2001
Top Story

Aviron raises $400 million

...and the other $200 million from a convertible note deal. Both deals were underwritten by Morgan Stanley Dean Witter...
BioCentury | Jan 12, 2001
Top Story

Aviron to sell follow-on, notes

...proposed a $150 million offering of convertible subordinated notes. The deals will be underwritten by Morgan Stanley Dean Witter...
BioCentury | Dec 27, 2000
Financial News

Rigel sells shoe

...IPO. The sale brings to $39.6 million the total raised in the deal, underwritten by Morgan Stanley Dean Witter...
Items per page:
1 - 10 of 65